Drug Name:
BLOXIVERZ Rx
Generic Name and Formulations:
Neostigmine methylsulfate 0.5mg/mL, 1mg/mL; soln for IV inj; latex-free.
Company:
Eclat Pharmaceuticals
Therapeutic Use:
Indications for BLOXIVERZ:
To reverse effects of non-depolarizing neuromuscular blocking agents (NMBAs) post-op.
Adults and Children:
See full labeling. Peripheral nerve stimulator and monitoring for twitch responses should be used to determine time of Bloxiverz initiation and the need for additional doses. Individualize. Give by IV inj slowly over a period of at least 1 min. Administer an anticholinergic (eg, atropine sulfate, glycopyrrolate) prior to (if bradycardia present) or concomitantly with Bloxiverz. Reversal of NMBAs with shorter half-lives (eg, rocuronium), or when first twitch response is substantially >10% of baseline or when a second twitch is present: 0.03mg/kg. Reversal of NMBAs with longer half-lives (eg, vecuronium, pancuronium) or when first twitch response is not substantially >10% of baseline or if rapid recovery required: 0.07mg/kg. Max total dose: 0.07mg/kg or up to a total of 5mg, whichever is less.
Contraindications:
Peritonitis. Mechanical obstruction of the intestinal or urinary tract.
Warnings/Precautions:
Should be administered by trained healthcare providers. Have treatment for anaphylaxis readily available. Maintain ventilation and patent airway. Increased risk of BP and HR complications with cardiovascular conditions (eg, coronary artery disease, cardiac arrhythmias, recent acute coronary syndrome) or myasthenia gravis. Neuromuscular dysfunction with large doses; reduce dose if recovery is nearly complete. Differentiate between myasthenic or cholinergic crisis. Renal or hepatic impairment; monitor closely. Elderly (monitor for longer periods). Labor & delivery: may induce premature labor. Pregnancy. Nursing mothers.
Interactions:
Caution with other drugs that may alter activity of metabolizing enzymes or transporters.
Pharmacological Class:
Cholinesterase inhibitor.
Adverse Reactions:
Bradycardia, nausea, vomiting, dry mouth, hypotension, dizziness, headache, insomnia, dyspnea, pruritus; hypersensitivity reactions.
Generic Availability:
YES
How Supplied:
Multi-dose vials (10mL)—10
Neurology Advisor Articles
- Multiple Sclerosis Guidelines: AAN's Recommendations for Initiating, Switching, Stopping Disease-Modifying Therapy
- Novel Therapy May Improve Symptoms in Early Huntington Disease
- Solriamfetol Associated With Improvement in Narcolepsy Types 1 and 2
- Interaction of Alcohol, Smoking on Multiple Sclerosis Severity
- Are Vaccines Associated With Multiple Sclerosis Relapse?
- The Symbiosis of Headache and Sleep
- Multiple Sclerosis Guidelines: AAN's Recommendations for Initiating, Switching, Stopping Disease-Modifying Therapy
- Neurosurgery in Parkinson Disease: A Brief History and Look Forward
- Blood Pressure-Dementia Link May Be Affected by Population Characteristics
- The Consequences of Compensation in Autism
- Wearable Sensors May Help Predict On, Off States in Parkinson Disease
- Pain, Psychiatric Comorbidities More Common in Chronic vs Episodic Migraine
- Adjunctive Eslicarbazepine Safe and Well Tolerated for Pediatric Seizures
- Erenumab Shown to Reduce Headache Days for Patients with Episodic Migraine
- New Zolmitriptan Intracutaneous System Safe and Effective for Migraine